

# **PRESS RELEASE**

# THE BOARD OF DIRECTORS HAS EXAMINED A CAPITAL AND FINANCIAL STREGTHENING PROGRAMME AND APPROVED THE INTERIM REPORT ON OPERATIONS AT 30 SEPTEMBER 2017

## **Equity and financial consolidation**

- The BoD has examined an important capital and financial strengthening programme for the Company, presented to the main banks the Group has relations with, with a total value of approximately EUR 400 million. The programme comprises a share capital increase of approximately EUR 200 million and the issue of additional financial instruments totalling approximately EUR 200 million which will go to consolidate the Company's financial structure.
- The Share Capital Increase will be optioned to shareholders at a price to be calculated prior to offering
  to the market. The Extraordinary Shareholders' Meeting asked to approve the operation shall be called
  at the next meeting of the BoD for a date subsequent to closure of FY2017. The majority shareholder
  has expressed its support for the operation.
- As part of the strengthening programme, the Company has commenced a constructive dialogue with the Group's main partner banks, also for the purpose of ongoing support for its business activities. The dialogue concerns the request to review the covenants of loan contracts, also further to the effects of impairment performed vis-à-vis Venezuela (see infra). The company is confident of obtaining the approvals needed for this request given the proposed capital and financial strengthening programme.
- Granting of a committed credit facility of EUR 120 million by Banca Intesa San Paolo, BNP Paribas, Banco BPM, HSBC and Unicredit, with specific conditions of use, was confirmed.

#### Results at 30 September 2017

- Approval of results at 30 September 2017 following the recent negative developments seen in Venezuela, impairment was performed resulting in a write-down for approximately EUR 230 million of the Group's total exposure to the country. The consolidated results were as follows further to the write-down:
  - 2% increase in total revenue to EUR 2.2 billion (EUR 2.1 billion at 30 September 2016) first positive effects of O&M activities
  - More than 6% increase in EBITDA to over EUR 302 million (EUR 285 million at 30 September 2016), with an EBITDA margin of 13.8%
  - o Further to the write-down:

- EBIT margin of 1.3%, with EBIT of over EUR 29 million (EUR 242 million at 30 September 2016)
- Net loss of approximately EUR 88 million (EUR 55 million net income at 30 September 2016)
- The positive business trend can be confirmed if we are to exclude the non-recurring write-down
  - o EBIT of over EUR 259 million (+7%), with an EBIT margin of 11.8%
  - Net profit totalled EUR 69 million (+23% YOY)
- EUR 2.2 billion of new orders, in keeping with the Group's strategy of focusing on countries with a lower risk profile
- Given the impairment performed, the Company feels that the guidance for 2017 already disclosed to the market on 2 August 2017 will be partly modified.
  - Revenue targets of +5%, approximately EUR 3.15 billion and EBITDA margin of 11-12% are confirmed
  - o New guidance for 2017:
    - EBIT margin (post-impairment): 3% 3.5%%;
    - Working capital (post-impairment) < EUR 600 million;
    - Working capital (pre-impairment) app. EUR 900 million EUR 1 billion;
    - Net financial debt app. EUR 1.15 billion
- The concession asset disposal programme is going ahead as planned.

000

# Main consolidated results at 30 September 2017

(Figures shown in EUR/000)

	30/09/2017 post-impairment <sup>(*)</sup>	30/09/2017 pre-impairment(**)	30/09/2016	YOY change pre- impairment <sup>(**)</sup>
Total revenue	2,189,329	2,189,329	2,150,805	+1.8%
EBITDA	302,127	302,127	284,782	+6.1%
EBITDA margin	13.8%	13.8%	13.2%	
Impairment(*)	(234,461)	(4,461)	(427)	NMF
EBIT	29,375	259,375	242,226	+7.1%
EBIT margin	1.3%	11.8%	11.3%	
Profit (loss) attributable to owners of the Parent	(87,689)	68,245	55,553	+22.8%

<sup>(\*)</sup> 

<sup>(\*\*)</sup> Figures shown without taking into account effects arising from impairment as detailed above.

Main financial position figures at 30 September 2017 (Figures shown in EUR/000)

	30/09/2017 post-impairment(*)	<b>30/09/2017</b> pre-impairment <sup>(**)</sup>	31/12/2016	30/09/2016
Total net non-current assets	1,352,436	1,100,199	1,007,371	948,187
Operating working capital	651,170	1,059,340	804,861	915,878
Total Provisions	(34,951)	34,951	(21,215)	(24,610)
Net invested capital	1,968,655	2,124,589	1,791,017	1,839,455
Total loans and borrowings/loan assets(***)	(1,392,262)	(1,392,262)	(1,092,532)	(1,231,132)
Total equity	576,392	732,326	698,485	608,323

<sup>(\*)</sup> Figures inclusive of effects arising from impairment of financial assets in Venezuela – for more details, see «Comment on operating performance».

000

## Capital and financial strengthening programme

*Rome, 14 November 2017* – The Board of Directors of Astaldi S.p.A., chaired by Paolo Astaldi, met today to examine a Group capital and financial strengthening programme.

This operation, which has a total value of approximately EUR 400 million, comprises a share capital increase of approximately EUR 200 million and the issue of additional financial instruments totalling approximately EUR 200 million which will go to consolidate the Company's financial structure.

The operation as a whole is aimed at strengthening the Group's capital and financial structure. In this regard, the share capital increase is also aimed at restoring capital following the effects of impairment on Venezuela and the issue of additional financial instruments represents a means to support implementation of the strategic plan, helping to consolidate the Group's competitive positioning, also as regards the strategy of geographical repositioning in markets with a lower risk profile (as outlined in the 2017-2021 Strategic Plan). This will also result in an increase of the Group's operating capacity in said markets of interest. The equity and financial consolidation programme is also aimed at strongly placing the Company with regard to the overall process of refinancing long-term debt, by extending due dates beyond 2022 and reducing the cost of debt, subject to market conditions.

The Share Capital Increase will be optioned to shareholders at a price to be calculated in useful time prior to the start of the public offer. To this end, the Extraordinary Shareholders' Meeting, asked to approve the operation, shall be called on a date subsequent to closure of FY2017.

The majority shareholder has expressed its interest in the operation.

The operation also includes the issue of additional financial instruments for approximately EUR 200 million, which will consolidate the Company's financial structure, the characteristics of which are being defined with the Group's partner banks.

<sup>(\*\*)</sup> Figures shown without taking into consideration the effects arising from impairment as detailed above.

<sup>(\*\*\*)</sup> Figure shown inclusive of treasury shares on hand amounting to EUR 3 million at 30 September 2017 and EUR 3.9 million at 31 December 2016 and EUR 4.2 million at 30 September 2016.

The operation also includes, based on specific conditions for its use, the granting of a committed credit facility of EUR 120 million by Banca Intesa San Paolo, BNP Paribas, Banco BPM, HSBC and Unicredit which has already been confirmed.

As part of the programme, the Company has commenced a constructive dialogue with the Group's main partner banks, also for the purpose of ongoing support for its business activities. The dialogue concerns the request to review the covenants of loan contracts, also further to the effects of impairment performed vis-à-vis Venezuela (see *infra*). The company is confident of obtaining the approvals needed for this request given the proposed capital and financial strengthening programme.

## Results at 30 September 2017

The Board of Directors of Astaldi S.p.A. also approved the Interim Report on Operations at 30 September 2017.

Astaldi Group's financial statements at 30 September 2017 reflect the effects of a conservative and cautious assessment of the Group's overall exposure as regards Venezuela.

In relation to recent negative and serious developments in the country, and in light of the findings of studies conducted with the help of an independent expert and international network, the Company while making a conservative assessment and adopting a cautious attitude, calculated the value of said exposure to be approximately EUR 203 million (from the nominal figure of EUR 433 million at 31 December 2016), reporting impairment of approximately EUR 230 million, even if it does not feel that the conditions are such as to presume complete loss of its claims.

If we are to exclude the consequences of impairment, the Group was able to confirm a good performance of business and earnings trends. Production at 30 September 2017 increased by 2% to EUR 2.2 billion (EUR 2.1 billion at 30 September 2016) and included the first benefits of diversification in the O&M segment which accounted for revenue of EUR 56 million (mainly in the hospital sector). EBITDA increased by over 6% to EUR 302.1 million (EUR 284.8 million at 30 September 2016), with an EBITDA margin of 13.8% (13.2% at 30 September 2016).

If we are to exclude the effects of non-recurring write-down on Venezuela, EBIT increased by over 7% to EUR 259.4 million, with an EBIT margin of 11.8% (respectively EUR 242.2 million in absolute terms and a margin of 11.3% at 30 September 2016), while net profit increased by approximately 23% to EUR 68.2 million with a net margin of 3.1% (respectively EUR 55.5 million in absolute terms and a margin of 2.6% at 30 September 2016). Following impairment, these values translate into EBIT of EUR 29.4 million with an EBIT margin of 1.3% and in a Group net loss of EUR 88 million.

More generally speaking, the financial statements for the first nine months of 2017 show the effects of decisive action to improve the overall risk profile of business activities (so-called strategic de-risking), which the Company is carrying out in keeping with the Strategic Plan and which has involved:

- (i) the Group's commercial profile, with the opening of new areas (Sweden, Georgia, Czech Republic), consolidation of more stable and less complex markets (Chile, Poland, Canada, USA), closure of countries no longer of strategic interest (Qatar), and gradual repositioning of the order backlog onto EPC contracts and O&M activities:
- (i) the earning profile, with the start-up of important works for the achievement of planned growth targets (specifically, in Poland, Chile, USA), but also with the re-planning of production activities in Canada, following positive settlement of the main difficulties linked to the Muskrat Falls hydroelectric project last December;

- (ii) the financial profile, with progressive execution of the asset disposal programme and, more generally, of the overall long-term debt refinancing plan. Specifically, at the reporting date, approximately 40% of what was scheduled to be disposed of by 2018 had already been disposed of; activities to reposition medium/long-term corporate debt on more staggered due dates were also started up, with the placement in June of EUR 140 million of unsecured equity-linked bonds falling due in 2024 and contextual repurchase of those already in circulation falling due in 2019;
- (iii) the balance sheet profile, with improvement of the quality of assets resulting from the previously mentioned reduction of exposure vis-à-vis Venezuela, with consequent rescaling of the overall risk related to assets.

The total order backlog remained solid, totalling over EUR 26 billion; EUR 15 billion of quarterly figure is to be attributed to the industrial backlog, the so-called core backlog (of which EUR 12.7 billion for construction and EUR 2.3 billion for O&M activities) and over EUR 11 billion to concession investments, the so-called total concessions backlog. The figure shown takes into account the commercial options and orders for which the Group has already been classified first in the award procedures of the relative contracts. If we exclude these figures, the order backlog in progress amounts to over EUR 18 billion, EUR 12 billion of which to the core backlog and the remaining 6 billion to investments in concession projects.

In keeping with the Strategic Plan, the Group's commercial action confirmed the gradual focus of activities on segments and geographical areas with a lower risk profile than in the past, showing an increasing incidence of EPC/construction contracts with independent financial profiles.

New orders for the period totalled EUR 2.3 billion, 80% of which referring to construction and with 60% referring to countries of greater strategic interest for the Company, in other words Chile, North America (Canada and USA), Northern and Central-Eastern Europe (Sweden, Georgia, Poland and Romania), and Italy. The total concessions backlog showed a reduction of EUR 1.6 billion further to progress of the asset disposal programme, to the partial benefit of O&M activities which accounted for EUR 453 million during the period. An additional EUR 1.4 billion of first classifieds in the Construction and O&M segments was also recorded (mainly in Romania, Italy, Canada, Panama and the Czech Republic), which it is felt can translate into new orders in the short-term further to completion of the relative award procedures. The book-to-bill ratio stood at 1.1x (calculated without taking into account first classifieds).

#### Main new orders

#### Romania

Frontieră-Curtici-Simeria Railway Line (Lots 2A and 2B) (*construction*) – EUR 776 million in total (Astaldi has a 42% interest), for the rehabilitation of approximately 80 kilometres of the Frontieră-Curtici-Simeria Railway Line forming part of the Pan-European Corridor IV.

Frontieră-Curtici-Simeria Railway Line (Lot 3) (*construction*) – EUR 600 million (Astaldi has a 49.5% interest), for the rehabilitation of approximately 40 kilometres of the Frontieră–Curtici–Simeria Railway Line, related to the stretch between Gurasada and Simeria of the 614 Km-Radna-Simeria section.

#### **Poland**

Warsaw Wschodnia Osobowa-Dorohusk Railway Line 7 (*construction*) - EUR 171 million, (Astaldi Group has a 95% interest and is leader of a JV) for upgrading the Warsaw Wschodnia Osobowa-Dorohusk Railway Line no. 7.

E-59 Railway (*construction*) – EUR 82 million for upgrading of a section of the E-59 Warsaw-Poznań Railway Line (Lot IV).

#### Turkey

Istanbul Underground (Mahmutbey-Bahçeşehir-Esenyurt section) (*construction*) - LIT 3 billion (approx. EUR 650 million) with Astaldi holding a 12% interest.

Istanbul Underground (Kirazli-Halkalı section) (*construction*) – EUR 627 million (Astaldi Group has a 15% interest) for performance of civil works and electro-mechanical systems of the new section of the Istanbul underground.

Menemen-Aliağa-Çandarli Motorway (*construction and operation*) – total investment of EUR 392 million, EUR 333 million of which for construction alone (Astaldi has a 33% interest).

#### Georgia

E-60 Motorway (Zemo Osiauri-Chumateleti, Lot 2) (*construction*) – GEL 300 million for the construction of approximately 8 kilometres of the E-60 Motorway, for the section between Zemo Osiauri and Chumateleti, part of the motorway corridor linking Tbilisi with the Black Sea.

#### Sweden

Gothenburg Underground (Haga Station) (*construction*) – for a total amount of EUR 245 million (SEK 2.3 billion, Astaldi has a 40% interest and is leader of a JV).

#### Italy

«Piemonte-Savoia» Italy-France HVDC Interconnection Project (Upper and Lower sections) (*construction*) – EUR 54 million for performance of civil works for the Italian section of the HVDC (High Voltage Direct Current) interconnection project in progress involving Italy and France.

Venice-Mestre Hospital (Ospedale dell'Angelo) (O&M) – over EUR 500 million following increase from 37% to 60.4% of the interest held by Astaldi Group in Veneta Sanitaria Finanza di Progetto S.p.A. (VSFP) further to acquisition of the shares held by Mantovani.

#### Main options and contracts to be finalised/funded to date

Carretera Omar-Torrijo | Panama (*construction*) – USD 89 million, equal to EUR 79 million, for expansion of the Carrettera Omar-Torrijo in Panama for which completion of the award procedure is pending.

Naples-Bari HS/HC Railway Line (Napoli-Cancello section) | Italy (construction) – EUR 397 million, Astaldi has a 40% interest, for design and construction of a first section of the high-speed, high-capacity Naples-Bari railway line and for the link to the Naples railway junction of the new Naples-Afragola HS Station (built by Astaldi). Completion of the procedure is pending for this project prior to signing of the contract.

Verona-Padua HS/HC Railway Line (Vicenza-Padua, 3<sup>rd</sup> Operational Lot) | Italy (*construction*) – The project refers to the contract phase for design and construction of the Verona-Padua high-speed, high-capacity railway line which ASTALDI holds a 37.49% interest in through Consorzio IRICAV 2, the General Contractor awarded the works. Specifically, the values entered among commercial options refer to Operational Lot 3 Vicenza-Padua.

La Punilla Hydroelectric Project | Chile (*construction and operation*) – Financial closing is pending for this project which involves the design, construction and operation of a multi-purpose hydroelectric plant with a storage capacity of 625 million m<sup>3</sup> and installed power of 94 MW.

The operating working capital totalled EUR 651.2 billion (EUR 804.9 million at 31 December 2016). The figure reflects the reduction in exposure as regards Venezuela which, following impairment, means reclassification of EUR 203 million referring to receivables net of impairment, from operating working capital to fixed assets by virtue of their nature of items considered collectable in the long-term at the reporting date. If we

are to exclude this non-recurring change, note must be taken of the inclusion among working capital of some slow-moving items, mainly referable to Romania, Algeria and Italy, which the Group feels it will be able to unwind in the short-term, also thanks to a dedicated task force. The working capital also includes receivables and works in progress accrued in Turkey – referring to the construction of additional sections of the Northern Marmara Highway (Third Bosphorus Bridge). Said additional works are regulated financially over a medium-term timeframe, compared to what is provided for in the basic contract, based on cash flow arising from the guaranteed minimums on additional kilometres. The Company is examining an operation to collect these amounts in advance through possible non-recourse factoring. Excluding all the items mentioned and the seasonal factors that are typical of the third quarter, operating working capital showed a regular trend which serves to confirm the improved financial profile of contracts in progress. This makes it possible to forecast a reduction of this item by the fourth quarter, also in light of the trend traditionally recorded in the last part of the year, as well as the unwinding expected for some of the items detailed above and the collection of additional contract advances for recently-acquired contracts (mainly abroad).

The Group's net financial exposure totalled EUR 1,389.2 million, compared to EUR 1,272 million at 30 June 2017 (EUR 1,088.7 million at 31 December 2016 and EUR 1,226.9 million at 30 September 2016). The figure listed reflects the effects of support provided for production and the significant commercial efforts the Group is making, as well as the effect arising from EUR 47 million of positive impact recorded at a total net financial position level following the sale of concession assets.

The disposal programme is also going ahead, with regard to which, as previously mentioned, over 40% of what was scheduled for disposal by 2018 has already been disposed of. The 2017 disposals already carried out refer to the investment in Pacific Hydro Chacayes S.A. (concession holder for the Chacayes plant in Chile), to 49% of SCMS (concession holder for the West Metropolitan Hospital in Santiago in Chile) and to 36.7% of M5 S.p.A. (concession holder for Line 5 of the Milan Underground in Italy). These are in addition to those already performed in previous years referring to Re.Consult (holder of an investment in A4 Holding S.p.A., the concession holder for the Brescia-Verona-Vicenza-Padua Motorway) and the car parks division.

As regards assets in Turkey, financial advisors (leading banks of international standing) have been appointed that will assist the Group with disposal, also in light of institutional investors' renewed interest in the country. Specifically, as regards the Third Bosphorus Bridge, it must be noted that disposal is scheduled by the end of the first half of 2018, with forecast collection of approximately EUR 200 million for the sale of the sole shareholder loan. Moreover, other activities are also being pursued for the sale of investments in additional concession projects, especially in the healthcare segment.

## Results of Q3 2017

## Main consolidated results of Q3 2017

(Figures shown in EUR/000)

	30/09/2017 post-impairment <sup>(*)</sup>	30/09/2017 pre-impairment (**)	30/09/2016	YOY change pre- impairment (**)
Total revenue	685,125	685,125	750,369	-8.7%
EBITDA	87,748	87,748	85,202	+3.0%
EBITDA margin	12.8%	12.8%	11.4%	_
Impairment(*)	(231,364)	(1,634)	(425)	NMF
EBIT	(155,326)	74,674	82,419	(9.4)%
EBIT margin	NMF	10.9%	11.0%	_
Profit (loss) attributable to owners of the Parent	(143,359)	12,575	24,044	(47.7)%

<sup>(\*)</sup> 

Astaldi Group's results in Q3 2017 reflect the effects of impairment of financial assets (receivables and works in progress) Venezuela which has been fully detailed above.

Total revenue amounted to EUR 685.1 million (-8.7%, EUR 750.4 million in Q3 2016), penalised in a YOY comparison by the lack of contributions from key contracts that were completed or largely completed during 2016 and in Q1 2017, as already mentioned. Revenue accounts for 94.8% of the results for the quarter and other operating revenue for the remaining 5.2%.

Cost structure and dynamics echoed those for the nine-month period, reflecting the trend and combination of production activities. Production costs dropped by 11% to EUR 445.6 million (EUR 500.5 million in Q3 2016), with a drop in the incidence on revenue from 66.7% to 65%. Personnel expense dropped by 5.6% to EUR 165.1 million (EUR 174.9 million in Q3 2016), with an incidence on revenue of 24.1% (23.3% in Q3 2016). Other operating costs decreased by 61.9% to EUR 5.3 million (EUR 13.9 million in Q3 2016), with a drop in the incidence on revenue to 0.8% (1.9% in Q3 2016)

Shares of profit/(loss) from joint ventures and associates dropped from 22.9% to EUR 18.7 million (EUR 24.2 million in Q3 2016), mainly following reclassification, as from 30 June 2017, of values referring to the investment in the Third Bosphorus Bridge concession holder (Turkey) among non-current assets held for sale.

EBITDA increased by 3% to EUR 87.7 million (EUR 85.2 million in Q3 2016), with an increase in the EBITDA margin to 12.8% (11.4% in Q3 2016).

Amortisation and depreciation increased to EUR 11.7 million from EUR 3.5 million in Q3 2016, further to the effects of net investments made during the quarter in question.

Impairment totalled EUR 231.6 million (EUR 425,000 in Q3 2016) and included approximately EUR 230 million of impairment in Venezuela, as mentioned above. As a result, EBIT totalled EUR (155.3) million (respectively, EUR 82.4 million in absolute terms and an 11% margin in Q3 2016).

<sup>(\*\*)</sup> Figures shown without taking into account effects arising from impairment as detailed above.

Net financial expense dropped by 7.1% to EUR 37.8 million (EUR 40.7 million in Q3 2016), with an incidence on revenue in line with the previous year (up to 5.5% from 5.4% in Q3 2016). EBT recorded a loss of EUR 193.1 million (respectively, EUR 41.7 million in absolute terms and a margin of 5.6% in Q3 2016).

The result of continuing operations totalled EUR (143.6) million (EUR 30 million in Q3 2016). Therefore, the result is a Group net loss of EUR 143.3 million (net profit of EUR 24 million in Q3 2016) which means a Group net profit of EUR 12.6 million if we are to exclude the effects of the Venezuela impairement.

#### Outlook

Impairment performed during Q3 2017 will not allow to meet the net profit targets forecast for year-end. Therefore, it is forecast that the year will end with a loss, albeit down on the figure for the first nine months, thanks to the positive business trend which was also confirmed at an EBITDA level for the first nine months.

From an industrial viewpoint, the de-risking of activities will continue over the coming months, with focus on areas with a lower risk profile than in the past and on EPC contracts that envisage contractual advances.

Strong commitment will be made to the debt refinancing programme. At the same time, efforts will be made to offload slow-moving working capital items and to proceed with the asset disposal programme and all other non-recurring actions planned to improve working capital management.

\*\*\*

This document does not constitute and is not part of any public offer of financial instruments pursuant to Articles 94 et seq. of the Consolidated Financial Act and of its implementing regulations. This document has not been approved by Consob, Borsa Italiana or any other competent authority. This document does not constitute an advertising message, an offer or an invitation to purchase or subscribe financial instruments (including shares), and this document (or part of it) will not constitute the basis of, or could it be relied upon in connection to, any investment agreement, obligation or decision. The financial instruments mentioned in this document are not and will not be registered pursuant to the United States Securities Act of 1933 (the "Securities Act"). The financial instruments referred to herein may not be offered or sold in the United States of America other than in the cases of exemption from the registration obligation provided for by the Securities Act. There will be no public offering of securities in the United States of America. The distribution of this documentation in certain Countries might be forbidden pursuant to the law. The information contained in this document is not an offer for sale in Canada, Japan, or Australia.

This document contains certain forward-looking statements, estimates and forecasts reflecting management's current views with respect to certain future events. Forward-looking statements, estimates and forecasts are generally identifiable by the use of the words "may," "will," "should," "plan," "expect," "anticipate," "estimate," "believe," "intend," "project," "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts, including, without limitation, those regarding the Company's future financial position and results of operations, strategy, plans, objectives, goals and targets and future developments in the markets where the Group participates. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements as a prediction of actual results. The issuer's ability to achieve its projected objectives or results is dependent on many factors which are outside management's control. Actual results may differ materially from (and be more negative than) those projected or implied in the forward-looking statements. Such forward-looking information involves risks and uncertainties that could significantly affect expected results and is based on certain key assumptions. All forward-looking statements included herein are based on information available as of the date hereof. No undertaking or obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law is accepted.

000

Astaldi's Manager in charge of Financial Reporting Paolo Citterio, General Manager – Administration and Finance hereby declares, pursuant to subsection 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained herein tallies with accounting documents, ledgers and entries.

ASTALDI GROUP is one of Italy's leading General Contractors, and among Europe's top 25 firms in the construction industry, where it also works as a sponsor of project finance initiatives. An international player for 90 years, it addresses the market by developing complex and integrated initiatives in the field of designing, building, and operating public infrastructures and large-scale civil engineering works, mainly in the areas of Transport Infrastructures, Energy Production Plants, Civil and Industrial Construction, Facility Management, Plant Engineering, and Management of Complex Systems. Listed on the stock market since 2002, it ended the 2016 financial year with a total order backlog of over EUR 27 billion and turnover of more than EUR 3 billion. It boasts more than 11,500 employees in Italy, Europe (Poland, Romania and Russia) and Turkey, Africa (Algeria), North America (Canada and the USA), Latin America, the Middle East (Saudi Arabia) and the Far East (Indonesia).

#### FOR FURTHER INFORMATION:

ASTALDI
Tel. +39 06.41766360
Alessandra Onorati / Anna Forciniti
External Relations and Investor Relations investor.relations@astaldi.com
www.astaldi.com

Italian Media: IMAGE BUILDING
Tel. +39 02.89011300
Simona Raffaelli / Alfredo Mele / Ilaria Mastrogregori astaldi@imagebuilding.it

International Media: FINSBURY
Edward Simpkins / Olivia Simpson
Tel. +44 20 7251 3801
astaldi@finsbury.com

# **ALLEGATI**

# **Reclassified Income Statement**

(Figures shown in thousands of Euro)

Other operating revenue         115,544         5.3%         93,560         4.3%           Total Revenue         2,189,329         100.0%         2,150,805         100.0%           Production cost         (1,400,180)         -64.0%         (1,437,805)         -66.8%           Added value         789,149         36.0%         713,000         33.2%           Personnel expenses         (496,944)         -22.7%         (452,130)         -21.0%           Other operating costs         (31,882)         -1.5%         (33,029)         -1.5%           Share of profits (losses) of joint ventures and associates         41,804         1.9%         56,941         2.6%           EBITDA         302,127         13.8%         284,782         13.2%           Amortisation and depreciation         (34,440)         -1.6%         (33,021)         -1.5%           Provisions         (3,851)         -0.2%         (9,108)         -0.4%           Impairment losses         (234,461)         -10.7%         (427)         0.0%           EBIT         29,375         1.3%         242,226         11.3%           Net financial expense         (145,279)         -6.6%         (136,250)         -6.3%           Pre-tax profit		30/09/2017		30/09/2016	
Total Revenue         2,189,329         100.0%         2,150,805         100.0%           Production cost         (1,400,180)         -64.0%         (1,437,805)         -66.8%           Added value         789,149         36.0%         713,000         33.2%           Personnel expenses         (496,944)         -22.7%         (452,130)         -21.0%           Other operating costs         (31,882)         -1.5%         (33,029)         -1.5%           Share of profits (losses) of joint ventures and associates         41,804         1.9%         56,941         2.6%           EBITDA         302,127         13.8%         284,782         13.2%           Amortisation and depreciation         (34,440)         -1.6%         (33,021)         -1.5%           Provisions         (3,851)         -0.2%         (9,108)         -0.4%           Impairment losses         (234,461)         -10.7%         (427)         0.0%           EBIT         29,375         1.3%         242,226         11.3%           Net financial expense         (145,279)         -6.6%         (136,250)         -6.3%           Pre-tax profit         (115,904)         -5.3%         105,976         4.9%           Tax expense         30,	Revenue	2,073,784	94.7%	2,057,245	95.7%
Production cost         (1,400,180)         -64.0%         (1,437,805)         -66.8%           Added value         789,149         36.0%         713,000         33.2%           Personnel expenses         (496,944)         -22.7%         (452,130)         -21.0%           Other operating costs         (31,882)         -1.5%         (33,029)         -1.5%           Share of profits (losses) of joint ventures and associates         41,804         1.9%         56,941         2.6%           EBITDA         302,127         13.8%         284,782         13.2%           Amortisation and depreciation         (34,440)         -1.6%         (33,021)         -1.5%           Provisions         (3,851)         -0.2%         (9,108)         -0.4%           Impairment losses         (234,461)         -10.7%         (427)         0.0%           EBIT         29,375         1.3%         242,226         11.3%           Net financial expense         (145,279)         -6.6%         (136,250)         -6.3%           Pre-tax profit         (115,904)         -5.3%         105,976         4.9%           Profit from continuing operations         (85,704)         -3.9%         78,828         3.7%           Profit (loss) attri	Other operating revenue	115,544	5.3%	93,560	4.3%
Added value         789,149         36.0%         713,000         33.2%           Personnel expenses         (496,944)         -22.7%         (452,130)         -21.0%           Other operating costs         (31,882)         -1.5%         (33,029)         -1.5%           Share of profits (losses) of joint ventures and associates         41,804         1.9%         56,941         2.6%           EBITDA         302,127         13.8%         284,782         13.2%           Amortisation and depreciation         (34,440)         -1.6%         (33,021)         -1.5%           Provisions         (3,851)         -0.2%         (9,108)         -0.4%           Impairment losses         (234,461)         -10.7%         (427)         0.0%           EBIT         29,375         1.3%         242,226         11.3%           Net financial expense         (145,279)         -6.6%         (136,250)         -6.3%           Pre-tax profit         (115,904)         -5.3%         105,976         4.9%           Tax expense         30,200         1.4%         (27,148)         -1.3%           Profit from continuing operations         (85,704)         -3.9%         78,828         3.7%           Profit for the year         <	Total Revenue	2,189,329	100.0%	2,150,805	100.0%
Personnel expenses       (496,944)       -22.7%       (452,130)       -21.0%         Other operating costs       (31,882)       -1.5%       (33,029)       -1.5%         Share of profits (losses) of joint ventures and associates       41,804       1.9%       56,941       2.6%         EBITDA       302,127       13.8%       284,782       13.2%         Amortisation and depreciation       (34,440)       -1.6%       (33,021)       -1.5%         Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit (loss) from discontinued operations       -0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0% <td>Production cost</td> <td>(1,400,180)</td> <td>-64.0%</td> <td>(1,437,805)</td> <td>-66.8%</td>	Production cost	(1,400,180)	-64.0%	(1,437,805)	-66.8%
Other operating costs       (31,882)       -1.5%       (33,029)       -1.5%         Share of profits (losses) of joint ventures and associates       41,804       1.9%       56,941       2.6%         EBITDA       302,127       13.8%       284,782       13.2%         Amortisation and depreciation       (34,440)       -1.6%       (33,021)       -1.5%         Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Added value	789,149	36.0%	713,000	33.2%
Share of profits (losses) of joint ventures and associates       41,804       1.9%       56,941       2.6%         EBITDA       302,127       13.8%       284,782       13.2%         Amortisation and depreciation       (34,440)       -1.6%       (33,021)       -1.5%         Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Personnel expenses	(496,944)	-22.7%	(452,130)	-21.0%
EBITDA       302,127       13.8%       284,782       13.2%         Amortisation and depreciation       (34,440)       -1.6%       (33,021)       -1.5%         Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Other operating costs	(31,882)	-1.5%	(33,029)	-1.5%
Amortisation and depreciation       (34,440)       -1.6%       (33,021)       -1.5%         Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Share of profits (losses) of joint ventures and associates	41,804	1.9%	56,941	2.6%
Provisions       (3,851)       -0.2%       (9,108)       -0.4%         Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	EBITDA	302,127	13.8%	284,782	13.2%
Impairment losses       (234,461)       -10.7%       (427)       0.0%         EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Amortisation and depreciation	(34,440)	-1.6%	(33,021)	-1.5%
EBIT       29,375       1.3%       242,226       11.3%         Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Provisions	(3,851)	-0.2%	(9,108)	-0.4%
Net financial expense       (145,279)       -6.6%       (136,250)       -6.3%         Pre-tax profit       (115,904)       -5.3%       105,976       4.9%         Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Impairment losses	(234,461)	-10.7%	(427)	0.0%
Pre-tax profit         (115,904)         -5.3%         105,976         4.9%           Tax expense         30,200         1.4%         (27,148)         -1.3%           Profit from continuing operations         (85,704)         -3.9%         78,828         3.7%           Profit (loss) from discontinued operations         -         0.0%         (23,634)         -1.1%           Profit for the year         (85,704)         -3.9%         55,195         2.6%           Profit (loss) attributable to non-controlling interests         (1,985)         -0.1%         358         0.0%	EBIT	29,375	1.3%	242,226	11.3%
Tax expense       30,200       1.4%       (27,148)       -1.3%         Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Net financial expense	(145,279)	-6.6%	(136,250)	-6.3%
Profit from continuing operations       (85,704)       -3.9%       78,828       3.7%         Profit (loss) from discontinued operations       -       0.0%       (23,634)       -1.1%         Profit for the year       (85,704)       -3.9%       55,195       2.6%         Profit (loss) attributable to non-controlling interests       (1,985)       -0.1%       358       0.0%	Pre-tax profit	(115,904)	-5.3%	105,976	4.9%
Profit (loss) from discontinued operations  - 0.0% (23,634) -1.1%  Profit for the year (85,704) -3.9% 55,195 2.6%  Profit (loss) attributable to non-controlling interests (1,985) -0.1% 358 0.0%	Tax expense	30,200	1.4%	(27,148)	-1.3%
Profit for the year         (85,704)         -3.9%         55,195         2.6%           Profit (loss) attributable to non-controlling interests         (1,985)         -0.1%         358         0.0%	Profit from continuing operations	(85,704)	-3.9%	78,828	3.7%
Profit (loss) attributable to non-controlling interests (1,985) -0.1% 358 0.0%	Profit (loss) from discontinued operations	-	0.0%	(23,634)	-1.1%
	Profit for the year	(85,704)	-3.9%	55,195	2.6%
Profit attributable to owners of the Parent (87,689) -4.0% 55,553 2.6%	Profit (loss) attributable to non-controlling interests	(1,985)	-0.1%	358	0.0%
	Profit attributable to owners of the Parent	(87,689)	-4.0%	55,553	2.6%

## Reclassified Statement of Financial Position

(Figures shown in thousands of Euro)

	30/09/2017	31/12/2016	30/09/2016
Property, plant, equipment and investment property	83,366	74,026	83,231
Equity investments	180,151	208,251	207,063
Other net non-current assets	392,398	523,631	500,105
Non-current assets held for sale	510,474	149,378	156,185
Liabilities directly associable with non-current assets held for sale	186,048	69,973	1,604
Property, plant, equipment and investment property		(17,888)	
Non-current assets (A)	1,352,436	1,007,371	948,187
Inventories	49,991	50,008	71,732
Contract work in progress	1,667,419	1,555,110	1,445,396
Trade receivables	58,627	57,327	27,712
Amounts due from customers	511,301	666,449	707,212
Other assets	251,646	199,632	138,719
Tax assets	65,306	94,537	113,872
Payments on account from customers	(543,894)	(492,856)	(397,582)
Subtotal	2,060,396	2,130,206	2,107,061
Trade payables	(56,808)	(61,352)	(68,982)
Payables to suppliers	(960,565)	(934,748)	(783,901)
Other liabilities	(391,853)	(329,245)	(338,301)
Subtotal	(1,409,226)	(1,325,346)	(1,191,183)
Operating working capital (B)	651,170	804,861	915,878
Employee benefits Non-current portion of provisions for risks and	(6,932)	(7,506)	(10,610)
charges	(28,018)	(13,709)	(14,000)
Total Provisions(C)	(34,951)	(21,215)	(24,610)
Net Invested Capital (D) = (A) + (B) + (C)	1,968,655	1,791,01b7	1,839,455
Cash and Cash equivalents	533,558	506,470	388,995
Current loan assets Current part of financial receivables from	46,099	25,227	16,965
concession	9,793		
Securities	249	848	1,126
Current Financial liabilities	(839,495)	(499,897)	(684,121)
Non current financial liabilities	(1,455,426)	(1,472,330)	(1,250,640)
Non recourse debt	(79,919)	(10,839)	(101,835)
Net financial position – disposal group	191,882	76,743	
Net loans and borrowings ( E )	(1,593,259)	(1,373,778)	(1,629,510)
Financial assets from concession activities	120,176	4,390	104,011
Non current financial receivables	80,821	276,856	294,367
Total net loans and borrowings ( F )	(1,392,262)	(1,092,532)	(1,231,132)
Equity attributable to owners of the parent	(544,688)	(692,384)	(602,904)
Equity attributable to non controlling interests	(31,704)	(6,101)	(5,419)
Equity ( G ) = ( D ) - ( F )	576,392	698,485	608,323

# Consolidated Cash-Flow

(€/000)

A) Cash-flow from operating activities	Nove mesi 2017 (321,981)	Nove mesi 2016 (248,438)
B) Cash-flow from investing activities	66,335	(44,609)
C) Cash-flow from financing activities	275,578	70,779
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	19,933	(222,268)
Cash and cash equivalent at the start of the period Cash and cash equivalent at the end of the period	513,625 <sup>(*)</sup> 533,558	611,263 388,995

<sup>(\*)</sup> Including cash and cash equivalents referred to disposal group, equal to €7.1 million.